The effects of hyperbaric oxygen therapy on the brain with middle cerebral artery occlusion.
Kitti ThiankhawSiriporn C ChattipakornSiripron C ChattipakornPublished in: Journal of cellular physiology (2020)
Middle cerebral artery occlusion (MCAO) causes focal cerebral hypoperfusion, resulting in cerebral ischemia or ischemic stroke. The main therapeutic approach is to restore an adequate blood flow to the brain via the process of reperfusion. However, rapid reperfusion can itself aggravate brain damage; this adverse effect is known as ischemic/reperfusion (I/R) injury. The pathological conditions that occur after cerebral ischemia and cerebral I/R are microvascular injury, blood-brain barrier dysfunction, post-ischemic inflammation, increased oxidative stress/reactive oxygen species, and a reduction in neuronal survival, leading to brain infarction. Animal and clinical studies on hyperbaric oxygen therapy (HBOT) have recently been carried out, and there is evidence of positive effects on neurological outcomes after cerebral ischemia. However, some evidence has shown that HBOT may not affect the functional recovery after ischemic injury. This review describes the current evidence, both in vivo and clinical data, regarding the potential benefits of HBOT after MCAO and cerebral I/R injury. The contrary data are also discussed to verify the effectiveness of HBOT in stroke outcomes.
Keyphrases
- cerebral ischemia
- blood brain barrier
- middle cerebral artery
- subarachnoid hemorrhage
- oxidative stress
- brain injury
- blood flow
- reactive oxygen species
- internal carotid artery
- randomized controlled trial
- electronic health record
- heart failure
- risk assessment
- systematic review
- white matter
- emergency department
- metabolic syndrome
- multiple sclerosis
- adipose tissue
- stem cells
- diabetic rats
- heat shock
- mesenchymal stem cells
- insulin resistance
- climate change
- free survival
- induced apoptosis
- artificial intelligence